Abstract: The present invention relates to methods for in vitro establishing, or diagnosing, high grade or low grade prostate cancer in a sample, preferably from a readily obtainable sample such as an urine, a prostatic fluid or ejaculate sample or a processed, or derived sample thereof, originating from human individual suspected of suffering from prostate cancer using expression level analysis of a combination of two, three or four molecular markers for prostate cancer. Based on establishing or diagnosing high grade or low grade prostate cancer in the disclosed methods, the methods further may include administering treatment for prostate cancer to the individual.
Type:
Application
Filed:
May 13, 2021
Publication date:
May 18, 2023
Applicant:
MDxHealth Research B.V.
Inventors:
Franciscus Petrus Smit, Daphne Hessels, Jacobus A. Schalken
Abstract: The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, HG, PrCa Met and CRPC. Specifically, the present invention relates to methods for in vitro diagnosing prostate cancer in a human individual comprising: 1) determining the expression of one or more genes chosen from the group consisting of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and/or UGT2B15; and 2) establishing up regulation of expression of said one or more genes as compared to expression of the respective one or more genes in a sample from an individual without prostate cancer thereby providing said diagnosis of prostate cancer.
Type:
Application
Filed:
April 27, 2021
Publication date:
August 12, 2021
Applicant:
MDxHealth Research B.V.
Inventors:
Franciscus Petrus Smit, Jack A. Schalken, Daphne Hessels
Abstract: The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, HG, PrCa Met and CRPC. Specifically, the present invention relates to methods for in vitro diagnosing prostate cancer in a human individual comprising: 1) determining the expression of one or more genes chosen from the group consisting of ACSM1, ALDH3B2, CGREF1, COMP, C19orf48, DLX1, GLYATL1, MS4A8B, NKAIN1, PPFIA2, PTPRT, TDRD1 and/or UGT2B15; and 2) establishing up regulation of expression of said one or more genes as compared to expression of the respective one or more genes in a sample from an individual without prostate cancer thereby providing said diagnosis of prostate cancer.
Type:
Application
Filed:
September 27, 2019
Publication date:
May 28, 2020
Applicant:
MDxHealth Research B.V.
Inventors:
Franciscus Petrus Smit, Jack A. Schalken, Daphne Hessels
Abstract: The present invention relates to methods for in vitro establishing, or diagnosing, high grade or low grade prostate cancer in a sample, preferably from a readily obtainable sample such as an urine, a prostatic fluid or ejaculate sample or a processed, or derived sample thereof, originating from human individual suspected of suffering from prostate cancer using expression level analysis of a combination of two, three or four molecular markers for prostate cancer. Based on establishing or diagnosing high grade or low grade prostate cancer in the disclosed methods, the methods further may include administering treatment for prostate cancer to the individual.
Type:
Application
Filed:
May 31, 2019
Publication date:
September 19, 2019
Applicant:
MDxHealth Research B.V.
Inventors:
Franciscus Petrus Smit, Daphne Hessels, Jacobus A. Schalken
Abstract: The present invention relates to methods, devices, combinations, kits, and systems for predicting and treating clinically significant prostate cancer in a urine sample of an individual suspected of suffering from prostate cancer based on expression analysis of normalized prostate tumor markers. The present methods, devices, combinations, kits, and systems are especially suitable for predicting and treating prostate cancer with a Gleason score of seven or more in individuals with a serum prostate-specific antigen (sPSA) level lower than 15 ng/ml.
Type:
Grant
Filed:
November 21, 2016
Date of Patent:
June 25, 2019
Assignee:
MDxHealth Research B.V.
Inventors:
Daphne Hessels, Franciscus Petrus Smit, Jack A. Schalken
Abstract: The present invention relates to methods, devices, combinations, kits, and systems for predicting and treating clinically significant prostate cancer in a urine sample of an individual suspected of suffering from prostate cancer based on expression analysis of normalised prostate tumour markers. The present methods, devices, combinations, kits, and systems are especially suitable for predicting and treating prostate cancer with a Gleason score of seven or more in individuals with a serum prostate-specific antigen (sPSA) level lower than 15 ng/ml.
Type:
Application
Filed:
November 21, 2016
Publication date:
May 25, 2017
Applicant:
MDxHealth Research B.V.
Inventors:
Daphne Hessels, Franciscus Petrus Smit, Jack A. Schalken
Abstract: The present invention relates to methods for in vitro establishing, or diagnosing, high grade or low grade prostate cancer in a sample, preferably from a readily obtainable sample such as an urine, a prostatic fluid or ejaculate sample or a processed, or derived sample thereof, originating from human individual suspected of suffering from prostate cancer using expression level analysis of a combination of two, three or four molecular markers for prostate cancer. Based on establishing or diagnosing high grade or low grade prostate cancer in the disclosed methods, the methods further may include administering treatment for prostate cancer to the individual.
Type:
Application
Filed:
February 12, 2016
Publication date:
July 7, 2016
Applicant:
MDxHealth Research B.V.
Inventors:
Franciscus Petrus Smit, Daphne Hessels, Jacobus A. Schalken